Vermillion, Inc announces that it has agreed with Quest Diagnostics to extend the Strategic Alliance Agreement between the parties through October, 2009.
DiaGenic ASA has announced that it has signed a service provider agreement with DNAVision,to offer its innovative blood-based gene-expression diagnostic test for early detection of breast cancer and Alzheimer’s disease.
Biosystems International has received venture capital amounting to $4.6 million to foster research and development of lung, colon, and breast cancer diagnostics to be marketed in 2010.
OraSure Technologies Inc announces that it has submitted a pre-market approval application to the FDA for its OraQuick HCV test, a rapid test for antibodies to the Hepatitis C virus (HCV).
Since bacteria rapidly evolve to evade the action of new antibiotics, the drugs quickly lose their effectiveness. A novel approach to the antibiotic problem, interestingly, is not an antibiotic at all but a new class of anti-microbial agent known as aganocides.
Just in time for a new flu season, in which up to 20% of Americans may be affected, 3M announces nationwide availability of the 3M Rapid Detection Flu A+B Test.
COLA, announces it has appointed Catherine Bernstein as Government Relations and External Affairs Manager.
AdvanDx announces that a new medical study demonstrated use of its PNA FISH test reduced mortality by 42% for patients with highly drug resistant Hospital-Acquired Enterococcus faecium bloodstream infections (BSIs)
A new study conducted in mice suggests that respiratory syncytial virus may hide in the lungs even after other symptoms abate, ultimately resurfacing to cause recurrent wheezing and chronic airway disease.
As the biopharmaceutical industry faces declining productivity and innovation, personalized medicine offers promise for increasing economic returns, according to “Assessing Risk and Return: Personalized Medicine Development & New Innovation Paradigm.”